Financial Results for Piramal Pharma Limited in FY26
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a prominent name in the global pharmaceutical industry, has recently shared its financial results for the Third Quarter (Q3) and the Nine Months (9M) of the fiscal year 2026, revealing key insights into its performance.
Consolidated Financial Overview
The financial reports indicate mixed results. The revenue from operations in Q3FY26 was ?2,140 crores, a slight decline of 3% from ?2,204 crores in Q3FY25. For the entire nine months, the revenue stood at ?6,117 crores, down by 4% compared to ?6,397 crores in the previous year.
Despite facing these challenges, Piramal Pharma managed to maintain a positive EBITDA margin of 11% in Q3FY26, although it was lower than the 16% margin reported in the previous year. The company has focused heavily on operational excellence and cost optimization, which has somewhat mitigated the impact of the revenue decline.
Key Business Highlights
Looking at the business segments, the Contract Development and Manufacturing Organization (CDMO) saw a significant drop in revenue, driven by factors such as inventory destocking from a major commercial product and uncertain recovery patterns in US biopharma funding.
CDMO Developments
In the first half of FY26, the order inflow was disappointing due to a slow recovery in funding and external regulatory delays. However, there is hope on the horizon, as the company has reported a considerable uptick in Requests for Proposals (RFPs) since October 2025, suggesting a potential rebound in orders driven by improved funding conditions.
CHG and Consumer Healthcare Advances
The Complex Hospital Generics (CHG) segment performed well, with the company acquiring Kenalog, a branded injectable product, which is expected to enhance its offerings in the market. In addition, the Consumer Healthcare (PCH) division has shown outstanding growth, particularly with power brands like Little's and Lacto Calamine.
PCH branded products achieved impressive YoY growth rates of 30% and 23% for Q3 and the nine-month period respectively. The company launched 31 new products and is investing significantly in media and promotions to boost sales further.
Investor Conference Call Announcement
Piramal Pharma Limited will host a conference call for investors and analysts to discuss these financial results. The call is scheduled for January 29, 2026, from 9:30 AM to 10:15 AM IST. Participants can expect insights into the financials, strategic directions, and future potential of Piramal Pharma's market position.
About Piramal Pharma Limited
Piramal Pharma Limited continues to stand out in the pharmaceutical market by offering a wide range of products and services through its robust production capabilities and an extensive global distribution network. The company operates in over 100 countries and comprises several business units, including Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare.
Through strategic investments and a commitment to innovation, Piramal Pharma remains focused on long-term growth and enhancement of its global footprint in the pharmaceutical industry.
Frequently Asked Questions
What were the key financial results for Q3 and 9M FY26?
Piramal Pharma reported a revenue of ?2,140 crores for Q3FY26, a 3% decrease compared to Q3FY25, with a nine-month total of ?6,117 crores.
What challenges did Piramal Pharma face in this period?
The company faced inventory destocking, slow order inflows due to funding uncertainties, and regulatory delays impacting the inhalation anesthesia market.
How did the CDMO segment perform?
The CDMO segment experienced a significant drop in revenue, attributed to earlier inventory management challenges and hesitant market conditions.
What growth initiatives is Piramal Pharma pursuing?
The company is investing in new product launches and has seen robust growth in its consumer healthcare segment, particularly from its power brands.
How can investors learn more about Piramal Pharma’s performance?
Investors can join the conference call scheduled for January 29, 2026, for detailed insights and updates from the company leadership.
